静脉注射富含IgM免疫球蛋白(pentaglobin)治疗脓毒症或脓毒性休克的临床疗效:一项Meta分析及试验序贯分析
本Meta分析系统检索PubMed、Cochrane Library、ISI Web of Knowledge和Embase四个数据库(自建库至2018年6月),纳入19项研究共1530例患者,评估静脉注射富含IgM免疫球蛋白(IVIgGM)治疗脓毒症和脓毒性休克的临床疗效。汇总分析显示IVIgGM降低脓毒症患者死亡风险(RR 0.60,95%CI 0.52–0.69,I²=0%),试验序贯分析显示对死亡率有显著效应;同时缩短机械通气时间(平均差-3.16天,95%CI -5.71至-0.61天),但未缩短ICU住院时间(平均差-0.38天,95%CI -3.55至2.80天)。GRADE量表显示获益的证据确定性为低。作者认为现有证据尚不足以支持在脓毒症治疗中广泛使用IVIgGM。
要点
- 19项研究共1530例脓毒症患者,IVIgGM使死亡风险降低(RR 0.60,95%CI 0.52–0.69,I²=0%)。
- 试验序贯分析显示IVIgGM对死亡率有显著效应。
- IVIgGM缩短机械通气时间(平均差-3.16天,95%CI -5.71至-0.61天),未缩短ICU住院时间(平均差-0.38天,95%CI -3.55至2.80天)。
- GRADE量表显示获益的证据确定性为低,仅纳入各项指标合格研究时治疗效应趋于更小或不一致。
- 现有证据尚不足以支持在脓毒症治疗中广泛使用IVIgGM。
适用人群与场景
- 成人脓毒症或脓毒性休克患者(19项研究共1530例)。
研究设计与关键结果
- 研究类型:Meta分析及试验序贯分析,系统检索PubMed、Cochrane Library、ISI Web of Knowledge和Embase四个数据库(自建库至2018年6月),纳入19项研究共1530例患者。
- 主要终点:IVIgGM降低脓毒症患者死亡风险(RR 0.60,95%CI 0.52–0.69,I²=0%)。
- 试验序贯分析显示IVIgGM对死亡率有显著效应。
- 次要终点:IVIgGM缩短机械通气时间(平均差-3.16天,95%CI -5.71至-0.61天),未缩短ICU住院时间(平均差-0.38天,95%CI -3.55至2.80天)。
- GRADE量表显示获益的证据确定性为低;仅纳入各项指标合格研究时治疗效应趋于更小或不一致。
证据类型、等级与局限
- 证据类型:Meta分析及试验序贯分析;采用GRADE量表评估证据确定性,获益的证据确定性为低。
- 局限:仅纳入各项指标合格研究时治疗效应趋于更小或不一致;现有证据尚不足以支持广泛使用IVIgGM。
对床旁实践的改变
- 作者认为,对成人脓毒症患者给予IVIgGM可能与死亡率降低相关。
- 作者认为,现有证据尚不足以支持在脓毒症治疗中广泛使用IVIgGM。
指南或共识出处
- PROSPERO注册号CRD42018084120,注册日期2018年2月11日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is characterized by a complex immune response. This meta-analysis evaluated the clinical effectiveness of intravenous IgM-enriched immunoglobulin (IVIgGM) in patients with sepsis and septic shock.
METHODS: Four databases, PubMed, the Cochrane Library, the ISI Web of Knowledge, and Embase, were systematically searched from inception to June 2018 to update the 2013 edition of the Cochrane review by two investigators, who independently selected studies, extracted relevant data, and evaluated study quality. Data were subjected to a meta-analysis and trial sequential analysis (TSA) for the primary and secondary outcomes. Level of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scale.
RESULTS: Nineteen studies comprising 1530 patients were included in this meta-analysis. Pooled analyses showed that the use of IVIgGM reduced the mortality risk of septic patients (relative risk 0.60; 95% confidence interval [CI] 0.52-0.69, I2 = 0%). TSA showed that IVIgGM had a significant effect on mortality. Additionally, the meta-analysis suggested that use of IVIgGM shortened length of mechanical ventilation (mean difference - 3.16 days; 95% CI - 5.71 to - 0.61 days) and did not shorten length of stay in the intensive care unit (mean difference - 0.38 days; 95% CI - 3.55 to 2.80 days). The GRADE scale showed that the certainty of the body of evidence was low for both benefits and IVIgGM.
CONCLUSION: Administration of IVIgGM to adult septic patients may be associated with reduced mortality. Treatment effects tended to be smaller or less consistent when including only those studies deemed adequate for each indicator. The available evidence is not clearly sufficient to support the widespread use of IVIgGM in the treatment of sepsis. Trial registration PROSPERO registration number: CRD42018084120. Registered on 11 February 2018.
参考来源
- Cui J, Wei X, Lv H, et al. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019. PMID: 30725235. doi:10.1186/s13613-019-0501-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。